Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: An experimental study

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 6, 2008, Pages 548-554

  Vaillant, Fanny ^a   Timour, Quadiri ^a,b   Descotes, Jacques ^b   Manati, Waheed ^a   Belhani, Dalila ^a   Bui Xuan, Bernard ^a   Tabib, Alain ^a   Bricca, Giampiero ^a   Chevalier, Philippe ^c  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c LOUIS PRADEL HOSPITAL   (France)

Author keywords

Cardioprotection; Heart rate reduction; Ivabradine; Ventricular fibrillation threshold

Indexed keywords

IVABRADINE; SUCCINATE DEHYDROGENASE; ANTIARRHYTHMIC AGENT; BENZAZEPINE DERIVATIVE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE FIBRILLATION; NONHUMAN; PRIORITY JOURNAL; SWINE; ACUTE DISEASE; ANIMAL; DISEASE MODEL; DOSE RESPONSE; ENZYMOLOGY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE PRESSURE; MALE; METABOLISM; PATHOPHYSIOLOGY; TIME;

ACTION POTENTIALS; ACUTE DISEASE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZAZEPINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; MALE; MITOCHONDRIA, HEART; MYOCARDIAL ISCHEMIA; SUCCINATE DEHYDROGENASE; SUS SCROFA; TIME FACTORS; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 59449087370     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181913df4     Document Type: Article

References (34)

1. Roelandt J, Klootwijk P, Lubsen J, et al. Sudden death during long-term ambulatory monitoring. Eur Heart J. 1984;5:7-20.
2. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 1989;69:1049-1169.
3. Timour Q, Aupetit JF, Loufoua-Moundanga J, et al. Class I antiarrhythmic drugs and myocardial ischaemia: study in the pig heart in situ. Naunyn Schmiedebergs Arch Pharmacol. 1991;343:645-651.
4. Aupetit JF, Timour Q, Larbre J, et al. Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia. Study in the porcine in situ heart. Cardiovasc Drugs Ther. 1993;7:217-223.
5. Aupetit JF, Timour Q, Loufoua-Moundanga J, et al. Profibrillatory effects of lidocaine in the acutely ischemic porcine heart. J Cardiovasc Pharmacol. 1995;25:810-816.
6. Bui-Xuan B, Aupetit JF, Freysz M, et al. Cardiac beta-adrenoreceptor activation and ventricular fibrillation under normal and ischemic conditions. Cardiovasc Res. 1996;32:1056-1063.
7. Aupetit JF, Frassati D, Bui-Xuan B, et al. Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration. Cardiovasc Res. 1998;37:646-655.
8. European Public Assessment Report (EPAR). Procoralan (2005). Available at: www.emea.europa.eu.
9. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drug. 2004;64:1757-1765.
10. Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002;282:H672-H679.
11. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674-1679.
12. Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659-666.
13. Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol. 2003;42:688-696.
14. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284:H676-H682.
15. Monnet X, Ghaleh B, Colin P, et al. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther. 2001;299:1133-1139.
16. Monnet X, Colin P, Ghaleh B, et al. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J. 2004; 25:579-586.
17. Thollon C, Bidouard JP, Cambarrat C, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S16257. Eur J Pharmacol. 1997;339:43-51.
18. Tabib A, Loire R. Quantitative morphometry of myocardial necrosis. Anatomical and enzymatic correlates, clinical index for estimating the amount of necrosed tissue. Arch Mal Coeur Vaiss. 1981;74:641-648.
19. Aupetit JF, Bui-Xuan B, Kioueh I, et al. Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization. Can J Physiol Pharmacol. 2000;78:208-216.
20. Vaillant F, Tsibiribi P, Bricca G, et al. Trimetazidine protective effect against ischemia-induced susceptibility to ventricular fibrillation in pigs. Cardiovasc Drugs Ther. 2008;22:29-36.
21. Aupetit JF, Timour Q, Freysz M, et al. Vulnerability to ventricular fibrillation related to ischemia: comparison of the acute effects of beta-blockers and calcium antagonists. Arch Int Pharmacodyn Ther. 1994;327: 25-39.
22. Timour Q, Aupetit JF, Freysz M, et al. Possible prevention by amlodipine of ventricular fibrillation related to brief ischemia episodes. Can J Physiol Pharmacol. 1996;74:1308-1314.
23. Timour Q, Bui-Xuan B, Faucon G, et al. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drugs Ther. 1996;10:447-454.
24. Bui-Xuan B, Aupetit JF, Freysz M, et al. Prevention by calcium antagonists of profibrillatory effects of class I antiarrhythmic drugs in acute myocardial ischemia: study in pig heart in situ. Pharmacotherapy. 1997;17:737-745.
25. Kleber AG. Extracellular potassium accumulation in acute myocardial ischemia. J Mol Cell Cardiol. 1984;16:389-394.
26. Renaud JF. Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther. 1988;1:677-686.
27. Lyons CJ, Burgess MJ, Abildskov JA. Effects of acute hyperkalemia on cardiac excitability. Am Heart J. 1977;94:755-763.
28. Ferrari R, Cargnoni A, Ceconi C. Anti-ischaemic effect of ivabradine. Pharmacol Res. 2006;53:435-439.
29. Hennersdorf MG. Possibilities of reducing heart rate by I(f)-channel inhibitor. Med Klin (Munich). 2006;101(Suppl 1):150-152.
30. Mahlberg-Gaudin FH, Bouly M, Chezaubernard C, et al. Pharmacological basis of f-current inhibition. Heart Drug. 2005;5:14-20.
31. Vilaine JP. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res. 2006;53:424-434.
32. Hindman MC, Wagner GS. Arrhythmias during myocardial infarction: mechanisms, significance, and therapy. Cardiovasc Clin. 1980;11:81-102.
33. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, et al. The effects of ropivacaine at clinically relevant doses on myocardial ischemia in pigs. J Anesth. 2006; 20:341-343.
34. Coronel R, Wilms-Schopman FJ, deGroot JR. Origin of ischemia-induced phase 1b ventricular arrhythmias in pig hearts. J Am Coll Cardiol. 2002; 39:166-176.